RxDoctor Payments Data

Dimitrios Angelis, MD

Cardiovascular Disease · Worcester, MANPI 1164469706

Payments from drug & device makers

$26,374in general payments, 2019–2025

Across 1,064 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Johnson & Johnson$2K
  • AstraZeneca$2K
  • Novartis$1K
  • Pfizer$1K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$370%
  • Speaking & faculty fees$1,5006%
  • Food & beverage$24,67494%
  • Education$1631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Actelion Pharmaceuticals US, Inc.154$3,022
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)21$2,235
Johnson & Johnson(2 entities)68$1,915
AstraZeneca89$1,806
Novartis72$1,401
Pfizer82$1,288
Lilly USA, LLC54$1,278
Amgen46$1,225
Medtronic(2 entities)28$1,089
Boehringer Ingelheim50$1,081
Bayer29$867
Novo Nordisk27$630
E.r. Squibb & Sons, L.L.C.26$559
Bardy Diagnostics, Inc.7$529
AbbVie19$507
Abiomed13$470
Inspire Medical Systems, Inc.21$446
Alnylam Pharmaceuticals Inc.16$411
GSK14$389
Boston Scientific6$276
Scpharmaceuticals Inc.13$270
Merck13$257
Takeda Pharmaceuticals U.S.A., Inc.11$249
Exact Sciences9$245
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$209
Lantheus Medical Imaging, Inc.8$188
Gilead8$177
Kiniksa Pharmaceuticals International, PLC7$168
Viiv Healthcare Company6$167
Sanofi-aventis U.S. LLC8$157
Amarin Pharma, Inc.8$145
Edwards Lifesciences6$145
Bridgebio Pharma, Inc.6$139
Cvrx, Inc.7$138
Aimmune Therapeutics, Inc.6$137
Vifor Pharma, Inc.7$129
Esperion Therapeutics, Inc.7$128
Biohaven Pharmaceutical Holding Company Ltd.5$113
Regeneron Healthcare Solutions, Inc.5$108
Daiichi Sankyo Inc.5$101
Nestle Healthcare Nutrition Inc.4$99
Abbott4$87
Sumitomo Pharma America, Inc.3$83
Z-medica, LLC3$81
Idorsia Pharmaceuticals US Inc3$69
Braintree Laboratories, Inc.3$68
Eisai Inc.3$67
Alcresta Therapeutics, Inc.3$67
Invivyd Inc2$65
Ardelyx, Inc.3$60
Stemline Therapeutics Inc.2$60
Kiniksa Pharmaceuticals, Ltd.3$59
Theratechnologies Inc.2$59
Madrigal Pharmaceuticals2$56
Otsuka America Pharmaceutical, Inc.2$53
Kowa Pharmaceuticals America, Inc.3$46
Astellas Pharma US Inc2$46
Insmed, Inc.2$42
Seqirus USA Inc2$40
Teva Pharmaceuticals USA, Inc.2$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,374 in reported general payments places this provider in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$153,441
Medicare patients
772
Services billed
2,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$471,990
EntrestoSacubitril/Valsartan89$122,025
JardianceEmpagliflozin45$53,648
FarxigaDapagliflozin Propanediol30$32,788
Repatha SureclickEvolocumab17$24,791
BrilintaTicagrelor24$21,229
XareltoRivaroxaban14$19,024
Metoprolol Succinate816$15,622
Atorvastatin Calcium590$10,471
Losartan Potassium806$9,493
Rosuvastatin Calcium161$6,624
Flecainide Acetate84$4,873
Carvedilol220$3,742
Ezetimibe89$3,530
ClopidogrelClopidogrel Bisulfate130$2,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,288$471,990349 claims
NovartisEntresto$1,401$122,02589 claims
AstraZenecaFarxiga, Brilinta$1,806$54,01754 claims
Boehringer IngelheimJardiance$1,081$53,64845 claims
Johnson & JohnsonXarelto$1,915$19,02414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →